2. Neuronal Signaling
  3. Tau Protein
  4. Armanezumab

Armanezumab is a pathological tau protein inhibitor that specifically binds to the N-terminal domain exposed by pathological tau protein (epitope covering amino acids 4-8: PRQEF). Armanezumab is applicable to research related to Alzheimer's disease, frontotemporal dementia, and Pick's disease.

For research use only. We do not sell to patients.

Armanezumab

Armanezumab Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Armanezumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Armanezumab is a pathological tau protein inhibitor that specifically binds to the N-terminal domain exposed by pathological tau protein (epitope covering amino acids 4-8: PRQEF). Armanezumab is applicable to research related to Alzheimer's disease, frontotemporal dementia, and Pick's disease[1].

Species Reactivity

Human
In Vitro

Armanezumab (3-243 nM) binds recombinant human 0N/4R tau protein with a high affinity, characterized by an equilibrium dissociation constant of 3.88E-08 M[1].
Armanezumab (0.02-12.5 μM; 1.5 h) specifically targets the PRQEF epitope (amino acids 4-8) of tau2-18, with amino acids 6 (glutamine) and 7 (glutamic acid) being essential for binding[1].
Armanezumab (1 μM; 16 h) partially protects SH-SY5Y human neuroblastoma cells from tau oligomer-mediated cytotoxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Armanezumab Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: SH-SY5Y human neuroblastoma cells
Concentration: 1 μM (Armanezumab pre-incubated with 0.5 μM tau oligomers)
Incubation Time: 16 h (cell incubation with oligomer-Armanezumab mixture)
Result: Restored SH-SY5Y cell viability to 89% compared to 36% viability in cells treated with tau oligomers alone, protecting cells from tau oligomer-mediated cytotoxicity.
In Vivo

Armanezumab (2 μg; intracranial injection; single dose) reduces total and multiple phosphorylated pathological tau species in the brains of THY-Tau22 tau transgenic mice 5 days after administration[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: THY-Tau22 tau transgenic mice (6-month-old)[1]
Dosage: 2 μg
Administration: intracranial injection (hippocampus and cortex); single dose
Result: Reduced total tau (HT7-stained) and phosphorylated tau species including pThr212, pSer214, pSer396/pSer404 (PHF1-stained), pThr212/pSer214 (AT100-stained), pThr231 (AT180-stained), and pSer202/pThr205 (AT8-stained) in the ipsilateral hemisphere compared to contralateral control IgG-injected hemisphere.
Confirmed neuronal integrity at injection sites via anti-NeuN staining.
Gene ID

4137  [NCBI]

Accession
Target

Tau
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[Armanezumab]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Armanezumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ArmanezumabTau ProteinN-terminal domain of pathological tautau transgenic mouseHEK293 cellsAlzheimer's diseaseCHO-DG44 cell lineHEK293T cellsPick's diseasefrontotemporal dementiapathological tauSH-SY5Y human neuroblastoma cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Armanezumab
Cat. No.:
HY-P992057
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.